AstraZeneca shares fall after Wainua misses late-stage heart trial target

AstraZeneca shares fell on Thursday after the company said Wainua failed to meet its primary goal in a late-stage trial for transthyretin-mediated amyloid cardiomyopathy, a rare and progressive heart disease.

The company said the phase 3 study did not show a statistically significant benefit on the trial's composite primary endpoint, which measured cardiovascular death and recurrent cardiovascular events. Market coverage of the announcement put AstraZeneca's decline at about 9%.

The setback matters because AstraZeneca had viewed the cardiomyopathy indication as a major expansion opportunity for Wainua, also known as eplontersen, which it developed with Ionis Pharmaceuticals. Analysts had seen the study as a potential route to meaningful additional sales in a difficult-to-treat disease area.

What the trial showed

The study enrolled 1,432 patients at 130 sites across 20 countries and followed them for 140 weeks. That scale made the readout one of the more important near-term tests of AstraZeneca's effort to widen Wainua beyond its current approved use.

AstraZeneca said the results still add to scientific understanding of treatment approaches for a condition that can be severe and often fatal. The company did not say the trial result changes Wainua's existing approval.

Wainua remains approved in more than 20 countries for hereditary transthyretin amyloidosis with polyneuropathy, a nerve-disease indication separate from the failed heart-disease study.

Market and strategic impact

Reports on the day said AstraZeneca lost roughly £20 billion to more than £22 billion in market value, although estimates varied by outlet. Ionis shares also fell after the trial failure, reflecting the shared development stake in the drug.

The result is a hit to AstraZeneca's diversification strategy. The company has been trying to broaden beyond oncology, and Wainua had been one of its more visible bets in rare disease and cardiovascular medicine.

The failure also raises questions about Wainua's commercial path in cardiomyopathy. Investors had treated the indication as a possible driver of peak sales, and a missed primary endpoint makes that path harder.

Analysts said the setback could force cuts to Wainua sales expectations and may damage management credibility. Even so, several said the trial result does not necessarily derail AstraZeneca's broader 2030 revenue target.

What happens next

The main open question is whether AstraZeneca and Ionis will still pursue any regulatory or scientific route forward for the cardiomyopathy indication. The research reviewed here does not show a new filing plan.

Another issue is how much analysts will trim longer-term estimates for the drug now that the main efficacy goal was missed. Further comment from the companies could also clarify whether subgroup or secondary-endpoint data point to any narrower path ahead.

For now, the story is one of a clear clinical setback with immediate market consequences. The drug's approved rare-disease business continues, but the hoped-for expansion into cardiomyopathy has taken a significant blow.